95 related articles for article (PubMed ID: 28737446)
1. Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims.
Palacharla RC; Nirogi R; Uthukam V; Manoharan A; Ponnamaneni RK; Kalaikadhiban I
Xenobiotica; 2018 Jul; 48(7):663-675. PubMed ID: 28737446
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
Nirogi R; Palacharla RC; Mohammed AR; Manoharan A; Ponnamaneni RK; Bhyrapuneni G
Chem Biol Interact; 2015 Mar; 230():9-20. PubMed ID: 25656918
[TBL] [Abstract][Full Text] [Related]
3. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6.
Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS
Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.
Walsky RL; Astuccio AV; Obach RS
J Clin Pharmacol; 2006 Dec; 46(12):1426-38. PubMed ID: 17101742
[TBL] [Abstract][Full Text] [Related]
5. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936
[TBL] [Abstract][Full Text] [Related]
6. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
[TBL] [Abstract][Full Text] [Related]
7. A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6.
Walsky RL; Obach RS
Drug Metab Dispos; 2007 Nov; 35(11):2053-9. PubMed ID: 17682072
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.
Micuda S; Mundlova L; Anzenbacherova E; Anzenbacher P; Chladek J; Fuksa L; Martinkova J
Eur J Clin Pharmacol; 2004 Oct; 60(8):583-9. PubMed ID: 15378224
[TBL] [Abstract][Full Text] [Related]
9. Dasotraline as a selective cytochrome 2B6 inhibitor for reaction phenotyping.
Yang X; Ryu S; Di L
Biopharm Drug Dispos; 2019 Nov; 40(9):358-361. PubMed ID: 31674039
[TBL] [Abstract][Full Text] [Related]
10. The mechanism and risk factors of clopidogrel-induced liver injury.
Zhai Y; Wang L; Yang F; Feng G; Feng S; Cui T; An L; He X
Drug Chem Toxicol; 2016 Oct; 39(4):367-74. PubMed ID: 26654298
[TBL] [Abstract][Full Text] [Related]
11. The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19.
Chen Y; Liu HF; Liu L; Nguyen K; Jones EB; Fretland AJ
Xenobiotica; 2010 Aug; 40(8):536-46. PubMed ID: 20528624
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro - in vivo extrapolation of hepatic clearance.
Palacharla RC; Uthukam V; Manoharan A; Ponnamaneni RK; Padala NP; Boggavarapu RK; Bhyrapuneni G; Ajjala DR; Nirogi R
Eur J Pharm Sci; 2017 Apr; 101():80-89. PubMed ID: 28179134
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
15. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
Chen Y; Liu L; Nguyen K; Fretland AJ
Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
17. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Hidestrand M; Oscarson M; Salonen JS; Nyman L; Pelkonen O; Turpeinen M; Ingelman-Sundberg M
Drug Metab Dispos; 2001 Nov; 29(11):1480-4. PubMed ID: 11602525
[TBL] [Abstract][Full Text] [Related]
18. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
[TBL] [Abstract][Full Text] [Related]
19. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
20. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
